United States Biotechnology & Medical Research

Constellation Pharmaceuticals Inc (CNST)

Track

Ticker: CNST Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Planned sale 22 Feb 2021
Value US$4,024,204.02 | Price 477.23 | Shares 21,166 (+6.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-02-23 2021-02-22 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
21,166 +6.0%
477.23
US$4,024,204 		21,166 +6.0% 477.23 US$4,024,204
2021-02-23 2021-02-19 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
39,714 -15.1%
338.99
US$4,563,093 		39,714 -15.1% 338.99 US$4,563,093
2021-02-19 2021-02-18 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
56,978 -21.3%
299.11
US$2,044,120 		56,978 -21.3% 299.11 US$2,044,120
2021-02-19 2021-02-17 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
410 -100.0%
37.56
US$15,398 		410 -100.0% 37.56 US$15,398
2021-02-19 2021-02-17 S Sale
3.9
COLUMN GROUP L P
Large shareholder
10,000 -9.2%
36.95
US$369,503 		10,000 -9.2% 36.95 US$369,503
2021-02-19 2021-02-17 S Sale
3.9
COLUMN GROUP L P
Large shareholder
10,000 -9.2%
36.95
US$369,503 		10,000 -9.2% 36.95 US$369,503
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
7,203 -100.0%
35.11
US$252,889 		7,203 -100.0% 35.11 US$252,889
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
1,227 -14.6%
33.69
US$41,342 		1,227 -14.6% 33.69 US$41,342
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
8,773 -51.0%
33.08
US$290,232 		8,773 -51.0% 33.08 US$290,232
2020-12-28 2020-12-21 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
4,020 -2.8%
35.02
US$140,769 		4,020 -2.8% 35.02 US$140,769
2020-12-22 2020-12-21 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
5,720 -100.0%
35.11
US$200,805 		5,720 -100.0% 35.11 US$200,805
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
233 -100.0%
38.35
US$8,936 		233 -100.0% 38.35 US$8,936
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
144 -38.2%
37.67
US$5,424 		144 -38.2% 37.67 US$5,424
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
212 -36.0%
36.59
US$7,757 		212 -36.0% 36.59 US$7,757
2020-05-13 2020-05-12 PlS Planned sale
Raythatha Jigar

See Remarks

Executive Director
9,209 -38.1%
50.17
US$461,981 		9,209 -38.1% 50.17 US$461,981
2020-05-13 2020-05-12 PlS Planned sale
1.6
Senderowicz Adrian

Chief Medical Officer

Officer
9,357 -37.1%
50.18
US$469,488 		9,357 -37.1% 50.18 US$469,488
2020-05-13 2020-05-12 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
4,225 -2.9%
50.05
US$211,474 		4,225 -2.9% 50.05 US$211,474
2020-05-13 2020-05-12 PlS Planned sale
Audia James E
Non-Executive Director
6,100 -19.3%
50.10
US$305,622 		6,100 -19.3% 50.10 US$305,622
2020-05-13 2020-05-11 PlS Planned sale
Raythatha Jigar

See Remarks

Executive Director
26 -0.2%
50.00
US$1,300 		26 -0.2% 50.00 US$1,300
2020-05-13 2020-05-11 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
100 -0.1%
50.00
US$5,000 		100 -0.1% 50.00 US$5,000
2020-05-12 2020-05-11 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
16,062 -100.0%
49.53
US$795,623 		16,062 -100.0% 49.53 US$795,623
2020-05-12 2020-05-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
12,741 -100.0%
49.53
US$631,055 		12,741 -100.0% 49.53 US$631,055
2020-05-07 2020-05-06 PlS Planned sale
Valentine Karen

See Remarks
12,566 -100.0%
40.10
US$503,897 		12,566 -100.0% 40.10 US$503,897
2020-05-07 2020-05-06 PlS Planned sale
Audia James E
7,500 -19.2%
45.15
US$338,600 		7,500 -19.2% 45.15 US$338,600
2020-05-07 2020-05-06 PlS Planned sale
2.2
GOLDSMITH MARK A
11,463 -7.4%
45.06
US$516,545 		11,463 -7.4% 45.06 US$516,545
2020-05-07 2020-05-06 PlS Planned sale
Trojer Patrick

Chief Scientific Officer
10,000 -100.0%
45.16
US$451,553 		10,000 -100.0% 45.16 US$451,553
2020-05-07 2020-05-05 PlS Planned sale
Valentine Karen

See Remarks
4,744 -100.0%
40.01
US$189,817 		4,744 -100.0% 40.01 US$189,817
2020-05-07 2020-05-05 PlS Planned sale
2.2
GOLDSMITH MARK A
3,145 -2.2%
40.01
US$125,824 		3,145 -2.2% 40.01 US$125,824
2020-04-29 2020-04-27 PlS Planned sale
Valentine Karen

See Remarks
400 -100.0%
40.13
US$16,052 		400 -100.0% 40.13 US$16,052
2020-04-29 2020-04-27 PlS Planned sale
2.2
GOLDSMITH MARK A
400 -0.3%
40.12
US$16,049 		400 -0.3% 40.12 US$16,049
2020-04-22 2020-04-20 PlS Planned sale
Valentine Karen

See Remarks
789 -100.0%
33.65
US$26,550 		789 -100.0% 33.65 US$26,550
2020-04-20 2020-04-17 PlS Planned sale
Valentine Karen

See Remarks
2,300 -100.0%
35.19
US$80,939 		2,300 -100.0% 35.19 US$80,939
2020-04-20 2020-04-17 PlS Planned sale
Reeve Emma

Chief Financial Officer
760 -100.0%
35.29
US$26,820 		760 -100.0% 35.29 US$26,820
2020-04-20 2020-04-16 PlS Planned sale
Valentine Karen

See Remarks
1,043 -100.0%
34.09
US$35,552 		1,043 -100.0% 34.09 US$35,552
2020-04-20 2020-04-16 PlS Planned sale
Valentine Karen

See Remarks
1,955 -65.2%
33.29
US$65,085 		1,955 -65.2% 33.29 US$65,085
2020-04-16 2020-04-14 PlS Planned sale
Reeve Emma

Chief Financial Officer
1,225 -100.0%
35.20
US$43,123 		1,225 -100.0% 35.20 US$43,123
2020-04-13 2020-04-09 PlS Planned sale
Reeve Emma

Chief Financial Officer
589 -100.0%
35.02
US$20,626 		589 -100.0% 35.02 US$20,626
2020-04-13 2020-04-09 PlS Planned sale
Reeve Emma

Chief Financial Officer
111 -100.0%
35.02
US$3,887 		111 -100.0% 35.02 US$3,887
2020-04-13 2020-04-09 PlS Planned sale
Valentine Karen

See Remarks
635 -100.0%
35.02
US$22,236 		635 -100.0% 35.02 US$22,236
2020-03-23 2020-03-20 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
5,539 +0.1%
23.15
US$128,228 		5,539 +0.1% 23.15 US$128,228
2020-03-23 2020-03-20 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
5,539 +0.1%
23.15
US$128,228 		5,539 +0.1% 23.15 US$128,228
2020-03-23 2020-03-19 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
36,135 +0.6%
22.38
US$808,701 		36,135 +0.6% 22.38 US$808,701
2020-03-23 2020-03-19 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
36,135 +0.6%
22.38
US$808,701 		36,135 +0.6% 22.38 US$808,701
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
130 -100.0%
32.92
US$4,279 		130 -100.0% 32.92 US$4,279
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
335 -72.0%
32.08
US$10,746 		335 -72.0% 32.08 US$10,746
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
152 -24.6%
31.17
US$4,738 		152 -24.6% 31.17 US$4,738
2020-02-14 2020-02-13 PlS Planned sale
Reeve Emma

Chief Financial Officer
5,521 -100.0%
35.06
US$193,539 		5,521 -100.0% 35.06 US$193,539
2020-02-14 2020-02-13 PlS Planned sale
Valentine Karen

See Remarks
4,473 -100.0%
35.07
US$156,859 		4,473 -100.0% 35.07 US$156,859
2020-02-14 2020-02-12 PlS Planned sale
Reeve Emma

Chief Financial Officer
1,103 -100.0%
35.02
US$38,624 		1,103 -100.0% 35.02 US$38,624
2020-02-14 2020-02-12 PlS Planned sale
Valentine Karen

See Remarks
1,500 -100.0%
35.02
US$52,527 		1,500 -100.0% 35.02 US$52,527
2020-02-12 2020-02-11 S Sale
Valentine Karen

See Remarks
8,550 -100.0%
35.03
US$299,506 		8,550 -100.0% 35.03 US$299,506
2020-02-12 2020-02-11 S Sale
Reeve Emma

Chief Financial Officer
1,430 -100.0%
35.04
US$50,107 		1,430 -100.0% 35.04 US$50,107
2020-02-12 2020-02-11 S Sale
Reeve Emma

Chief Financial Officer
7,212 -100.0%
35.04
US$252,708 		7,212 -100.0% 35.04 US$252,708
2020-02-12 2020-02-10 S Sale
Valentine Karen

See Remarks
14,096 -100.0%
33.51
US$472,357 		14,096 -100.0% 33.51 US$472,357
2020-02-12 2020-02-10 S Sale
Reeve Emma

Chief Financial Officer
200 -100.0%
35.00
US$7,000 		200 -100.0% 35.00 US$7,000
2019-12-16 2019-12-13 B Purchase Venrock Healthcare Capital Partners III, L.P. Large shareholder
400,000 +11.1%
34.50
US$13,800,000 		400,000 +11.1% 34.50 US$13,800,000
2019-12-16 2019-12-13 B Purchase EVNIN ANTHONY B Non-Executive Director
400,000 +7.5%
34.50
US$13,800,000 		400,000 +7.5% 34.50 US$13,800,000
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
726 -100.0%
30.84
US$22,390 		726 -100.0% 30.84 US$22,390
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
15,740 -95.6%
29.75
US$468,260 		15,740 -95.6% 29.75 US$468,260
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
11,976 -42.1%
20.01
US$239,631 		11,976 -42.1% 20.01 US$239,631
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
6,188 -17.9%
19.20
US$118,839 		6,188 -17.9% 19.20 US$118,839
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
24,264 -41.2%
18.40
US$446,518 		24,264 -41.2% 18.40 US$446,518
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
4,158 -6.6%
17.59
US$73,158 		4,158 -6.6% 17.59 US$73,158
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
2,574 -3.9%
16.31
US$41,979 		2,574 -3.9% 16.31 US$41,979
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
350 -2.3%
36.01
US$12,602 		350 -2.3% 36.01 US$12,602
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
20,200 -56.9%
35.23
US$711,579 		20,200 -56.9% 35.23 US$711,579
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
12,095 -25.4%
31.32
US$378,795 		12,095 -25.4% 31.32 US$378,795
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
29,005 -37.9%
30.19
US$875,528 		29,005 -37.9% 30.19 US$875,528
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
20,550 -21.2%
25.06
US$514,952 		20,550 -21.2% 25.06 US$514,952
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
3,170 -3.2%
21.20
US$67,198 		3,170 -3.2% 21.20 US$67,198
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
17,380 -14.8%
20.18
US$350,727 		17,380 -14.8% 20.18 US$350,727
2019-11-08 2019-11-06 PlS Planned sale Audia James E
7,500 -16.1%
19.11
US$143,356 		7,500 -16.1% 19.11 US$143,356
2019-11-08 2019-11-06 PlS Planned sale Audia James E
10,500 -18.4%
18.58
US$195,076 		10,500 -18.4% 18.58 US$195,076
2019-11-08 2019-11-06 PlS Planned sale Audia James E
4,500 -7.3%
17.55
US$78,978 		4,500 -7.3% 17.55 US$78,978
2019-11-08 2019-11-06 PlS Planned sale Senderowicz Adrian

Chief Medical Officer
5,451 -25.5%
35.11
US$191,394 		5,451 -25.5% 35.11 US$191,394
Explore more

More insider trading research around Constellation Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America